Pfizer Inc (BUE:PFE)
ARS 7671.5 110 (1.45%) Market Cap: 142.34 Til Enterprise Value: 192.49 Til PE Ratio: 0 PB Ratio: 1.75 GF Score: 58/100

Pfizer Inc to Discuss Updated Phase 1 Dose Escalation Data for ARV-471 Call Transcript

Dec 10, 2021 / 01:30PM GMT
Release Date Price: ARS5521 (+0.02%)
Operator

Good morning, ladies and gentlemen, and welcome to the Arvinas and Pfizer conference call. (Operator Instructions)

I would now like to turn the call over to Jeff Boyle, Vice President, Investor Relations at Arvinas. Please proceed.

Jeff Boyle
Arvinas, Inc. - VP of IR

Thank you, operator. Good morning, everyone, and thank you for joining us to discuss the ARV-471 dose escalation clinical trial results presented this morning at San Antonio Breast Cancer Symposium. Earlier this morning, we issued a press release highlighting these data, which can be accessed in the Investors section of our website at arvinas.com.

With me today are Arvinas President and Chief Executive Officer, John Houston; Arvinas Chief Medical Officer, Ron Peck; and Pfizer Oncology Chief Development Officer, Chris Boshoff. Ian Taylor, our Chief Scientific Officer, will join for the Q&A portion of the call.

Before we begin the call, I'd like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot